Ready-made stem cell therapies for pets could be coming | TechCrunch https://t.co/ukOEqmlBkX ...

Financial Data and Key Metrics Changes - PetVivo reported a record revenue of $1.1 million for fiscal year 2025, reflecting a 17% increase compared to the previous year [4][7] - Gross profit totaled $995,000, representing a gross margin of 87.8%, which is a slight decrease from 89.5% in fiscal year 2024 [8] - Operating expenses decreased by 21% to $9.1 million, primarily due to a strategic cost reduction program [8] - The net loss improved by 27% to $8 million, or $0.39 per share, compared to a net loss of $11 million, or $0.78 per share in fiscal year 2024 [9] Business Line Data and Key Metrics Changes - The expanding nationwide distributor network contributed $958,000 in sales, accounting for 86% of total revenues, with a 31% increase in their combined sales [7][8] - The company is focusing on increasing its market share in the companion animal segment while maintaining growth in the equine market [4][5] Market Data and Key Metrics Changes - The veterinary healthcare market in Mexico is projected to grow at a 6% CAGR, reaching nearly $2 billion by 2026, presenting a significant opportunity for PetVivo [3] - The U.S. animal health market is projected to double to $11.3 billion by 2030, providing substantial growth potential for the company [18] Company Strategy and Development Direction - The company aims to drive greater adoption of its products, particularly Spring and Precise PRP, by increasing awareness among key decision-makers in the veterinary field [11][12] - Strategic partnerships and collaborations, such as with Digital Landia and Commonwealth Markets, are expected to enhance product visibility and market penetration [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong sales momentum and market penetration expected in fiscal year 2026 [17] - The company is well-positioned to accelerate growth and expand into high-growth markets, driven by trends in pet ownership and advancements in veterinary care [18][19] Other Important Information - The company filed for an extension for its Form 10-K filing to allow auditors to complete their review, meaning all financial results presented are preliminary and unaudited [2][7] - The company raised net proceeds of $4.7 million from a Series B convertible preferred stock offering to support growth strategies [10] Q&A Session Summary Question: How much dilution do you expect from the conversion of the Series B preferred? - Management indicated that the conversion is on a one-to-one basis, with an additional 5 million shares expected if fully converted [30][32] Question: What is the average price per vial of the Spring injection that veterinarians are charging for canines? - The average charge by veterinary doctors is around $800 per joint, with variations between $500 to $1,200 depending on the complexity of the issue [36] Question: Can you talk a little bit about the human trials and their projected outcomes? - Management discussed ongoing studies with BioPiezo, showing promising results in small and large animals, with potential applications in the human market for osteoarthritis [46]

Q3 2024 Forward Looking Statements These materials have been prepared for informational purposes only in relation to Zomedica and are not, under any circumstances, to be construed as an offering of any securities for sale directly or indirectly in any province or territory of Canada, in the United States or in the territories or possessions thereof. Prospective investors should not construe the contents of this presentation as legal, tax, financial, investment or other advice. Each investor should make thei ...

Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the “Delinquency Letter”), notifying the Company that it is not in compliance with the requirements for continued list ...

The University of Florida Veterinary Hospital, a leader in advanced veterinary care and research, is now licensed and equipped to deliver IsoPet therapy as part of its oncology services. This certification expands the availability of a targeted, minimally invasive cancer treatment that uses a proprietary radionuclide injection to treat solid tumors in pets. Kennewick, WA, May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced that the University of Florida Veterinary Hospital has been cer ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO and TreasurerJay Mazelsky - President and CEOMichael Ryskin - Managing DirectorKatarina Markovic - Executive DirectorJonathan Block - Managing DirectorDaniel Clark - VP - Equity Research Conference Call Participants Erin Wright - AnalystBrandon Vazquez - Research AnalystDavid Westenberg - Managing Director & Senior Research AnalystNavann Ty Dietschi - Lead Analyst Operator Good mo ...

IDEXX Laboratories (IDXX) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the IDEXX Laboratories First Quarter twenty twenty five Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay Mazelski, President and Chief Executive Officer Andrew Emerson, Chief Financial Officer and John Rebus, Vice President, Investor Relations. IDEXX would like to preface the discussion today with a caution regarding forwa ...

Zomedica (ZOM) Q4 2024 Earnings Call March 13, 2025 04:30 PM ET Company Participants Mike Vallie - Managing DirectorLarry Heaton - President & CEOMike Zuehlke - Vice President of Finance & Corporate ControllerScott Jordan - Executive VP of Finance & CFOAndrew Rem - Portfolio Manager Conference Call Participants Robert Leboyer - Senior Biotechnology AnalystRobert Sassoon - Senior Research Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the Zomedica Fourth Quarter twenty twenty four Fina ...

IDEXX Laboratories (IDXX) Q4 2024 Earnings Call February 03, 2025 08:30 AM ET Company Participants Brian McKeon - Executive VP & CFOAndrew Emerson - Senior VP - Corporate & CAG FinanceJay Mazelsky - President and CEOChris Schott - Managing DirectorJonathan Block - Managing DirectorDaniel Clark - VP - Equity Research Conference Call Participants Erin Wright. - Senior Healthcare Equity Research AnalystMichael Ryskin - AnalystNavann Ty Dietschi - Lead Analyst Moderator Good morning, and welcome to the IDEXX La ...